This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ZEAL Zealand Pharma A/S (ZEAL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Zealand Pharma A/S Stock (NASDAQ:ZEAL) 30 days 90 days 365 days Advanced Chart Remove Ads Get Zealand Pharma A/S alerts:Sign Up Key Stats Today's Range N/A50-Day Range$16.54▼$19.2052-Week Range N/AVolumeN/AAverage Volume4,965 shsMarket Capitalization$818.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.Read More… Remove Ads Receive ZEAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address ZEAL Stock News HeadlinesResolutions from Zealand Pharma's Annual General Meeting 2025March 27, 2025 | globenewswire.comZealand Pharma major shareholder announcement: Van Herk Investments B.V.March 25, 2025 | globenewswire.comNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America. April 6, 2025 | Paradigm Press (Ad)Zealand Pharma increases its share capital as a result of the exercise of employee warrantsMarch 20, 2025 | globenewswire.comEnrolment concludes in Zealand’s Phase IIb obesity therapy trialMarch 19, 2025 | msn.comRoche’s obesity deal with Zealand Pharma tees up rival for GLP-1sMarch 17, 2025 | finance.yahoo.comZealand Pharma completes enrollment in ZUPREME-1 trialMarch 17, 2025 | markets.businessinsider.comZealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesityMarch 17, 2025 | globenewswire.comSee More Headlines ZEAL Stock Analysis - Frequently Asked Questions How were Zealand Pharma A/S's earnings last quarter? Zealand Pharma A/S (NASDAQ:ZEAL) issued its earnings results on Wednesday, November, 10th. The company reported ($4.61) earnings per share for the quarter, topping the consensus estimate of ($6.31) by $1.70. The business had revenue of $16.87 million for the quarter, compared to analyst estimates of $12.21 million. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 111.04% and a negative net margin of 565.44%. When did Zealand Pharma A/S IPO? Zealand Pharma A/S (ZEAL) raised $75 million in an initial public offering on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. What other stocks do shareholders of Zealand Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zealand Pharma A/S investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), Editas Medicine (EDIT), Spectrum Pharmaceuticals (SPPI), AbbVie (ABBV) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings11/10/2021Today4/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ZEAL CIK1674988 Webwww.zealandpharma.com Phone(458) 877-3600Fax45-8877-3898Employees355Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-161,990,000.00 Net Margins-565.44% Pretax Margin-364.34% Return on Equity-111.04% Return on Assets-56.54% Debt Debt-to-Equity Ratio0.93 Current Ratio4.79 Quick Ratio4.78 Sales & Book Value Annual Sales$46.54 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$3.38 per share Price / BookN/AMiscellaneous Outstanding Shares46,538,000Free Float45,514,000Market Cap$818.60 million OptionableNot Optionable Beta1.45 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ZEAL) was last updated on 4/6/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThinking of buying Nvidia? Read this firstI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zealand Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Zealand Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.